...
首页> 外文期刊>British Journal of Cancer >Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients
【24h】

Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients

机译:从恶病质癌症患者尿液中分离出的产物诱导小鼠恶病质

获取原文

摘要

Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month(-1)). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200,000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of M(r) 24,000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice.
机译:患有体重减轻的癌症患者的尿液显示存在M(r)24,000抗原,该抗原由单克隆抗体检测到,该单克隆抗体是由患有癌症恶病质的小鼠脾细胞融合而形成的。正常受试者,因癌症以外的其他原因导致体重减轻的患者,体重稳定或体重减轻较轻的癌症患者(1 kg month(-1))的尿液中不存在抗原。该抗原存在于患有胰腺癌,乳腺癌,肺癌和卵巢癌的受试者的尿液中。使用亲和色谱法与小鼠单克隆抗体和反相高效液相色谱法(HPLC)相结合,从尿液中纯化抗原。通过凝胶银染确定,该方法得到的蛋白质纯化量比原始尿液提取物中的蛋白质高200,000倍,分离出的物质是均匀的。 N端氨基酸序列与任何公认的细胞因子均无同源性。与接受以相同方式从正常受试者的尿液中纯化的物质的对照组相比,向小鼠施用这种物质导致体重显着降低(P <0.005)。在不减少食物和水摄入的情况下发生了体重减轻,并且通过事先施用小鼠单克隆抗体可以防止体重减轻。身体成分分析表明,fat体脂肪和脱脂脂肪均减少,而含水量没有变化。在用单克隆抗体治疗的小鼠中,对身体组成的影响被逆转。蛋白质合成减少,骨骼肌降解增加。蛋白质降解与前列腺素E2(PGE2)释放增加有关。在用单克隆抗体预处理的小鼠中,蛋白质降解和PGE2释放均显着降低。这些结果表明存在于恶病质癌症患者尿液中的M(r)24,000物质能够在小鼠中产生恶病质综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号